Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.54 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216089 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL29966546 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL8516937 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL4809869 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL9566045 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL4809860 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL16298755 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL9566182 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL9566048 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL30703113 | 0.93 | CD69 (0.61) | CD69ALDH1A1THRBMAPK1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633372-B2 | Decoding approaches for protein identification | NAUTILUS SUBSIDIARY, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260004881-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEINS | NAUTILUS SUBSIDIARY INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250342902-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250292870-A1 | METHODS AND SYSTEMS FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025049634-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250034565-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20250037789-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12148509-B2 | Decoding approaches for protein identification | NAUTILUS SUBSIDIARY, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3701066-B1 | METHODS AND SYSTEMS FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4372383-A2 | METHODS AND SYSTEMS FOR PROTEIN IDENTIFICATION | Nautilus Subsidiary, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11721412-B2 | Methods for identifying a protein in a sample of unknown proteins | NAUTILUS SUBSIDIARY, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230117795-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS BIOTECHNOLOGY, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11545234-B2 | Decoding approaches for protein identification | NAUTILUS BIOTECHNOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11282586-B2 | Decoding approaches for protein identification | NAUTILUS BIOTECHNOLOGY, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11282585-B2 | Decoding approaches for protein identification | NAUTILUS BIOTECHNOLOGY, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220068431-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260004881-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEINS | PTMS, SRMS, CHAMP1 | CD69 406/4885ALDH1A1 4839/4885THRB 1380/4885 |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | SIGLEC7, SIGLEC9, ENGASE | CD69 185/4885ALDH1A1 4283/4885THRB 1350/4885 |
| US-12633372-B2 | Decoding approaches for protein identification | HSPBP1, SRP19, SRP9 | CD69 1133/4885ALDH1A1 4672/4885THRB 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.